Although the optimal staining cutoff and optimal assay for determining PD-L1 expression as it pertains to therapeutic responses remain controversial, these data indicate a higher likelihood of PD-L1 positivity in dMMR mCRPC (mixed-effects logistic regression model odds ratio [OR], 14; 95% CI, 2–84; P = 0.005), providing further evidence for dMMR as a potential predictive biomarker for immune checkpoint inhibition in lethal prostate cancer. This evidence concerns the gene CD274 and prostate carcinoma.